Recent Updates
Recently added Catalysts
UPC Negative Sentiment

Universe Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed Annual Report Ji'an, Jiangxi, China

Key Takeaway: Universe Pharmaceuticals INC has received a staff determination notice from Nasdaq due to its failure to file its Annual Report on Form 20-F for the fiscal year ending September 30, 2024. This delinquency presents a risk of delisting from the stock exchange. The company intends to request a stay of suspension before the specified date and is actively working to complete the overdue report. This announcement is in compliance with Nasdaq's rules regarding deficiency notifications.
Price reaction · baseline $6.392 (2025-02-24 close) · hit after-hours · clean, no other UPC news in the window
day 0 close
-6.1%
day 1
-4.1%
day 3 · peak
-20.1%

Market Sentiment Analysis

CONCERNS & RISKS

  • Company received a determination notice from Nasdaq for delayed filing.
  • Failure to file the Annual Report may lead to delisting from Nasdaq.
  • Company is currently in front of a Hearings Panel regarding compliance issues.

Full Press Release Details

Universe Pharmaceuticals INC Receives Staff Determination Notice from
Nasdaq Related to Delayed Annual Report
Ji'an, Jiangxi, China, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the "Company") (Nasdaq: UPC), a pharmaceutical producer and distributor
in China, today announced that on February 19, 2025, the Company received a staff determination notice from the Listing Qualifications
Department of the Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that it is delinquent in filing its Annual Report
on Form 20-F for the fiscal year ended September 30, 2024 (the "Form 20-F") and that this matter serves as an additional basis
for delisting the Company's securities from Nasdaq. The failure to timely file the Form 20-F is a violation of Nasdaq Listing Rule
The Company is before a Hearings Panel for its
failure to comply with Listing Rule 5550(a)(2) and was therefore provided until February 26, 2025 to request a stay of the suspension
of the Company's securities, pending a Hearings Panel decision. The Company intends to request a stay of the suspension before that
date. The Company is working on completing and filing the delayed Form 20-F.
This announcement is being made in compliance
with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.
About Universe Pharmaceuticals INC
Universe Pharmaceuticals INC, headquartered in
Ji'an, Jiangxi, China, is a pharmaceutical producer and distributor in China. The Company specializes in the manufacturing, marketing,
sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical
conditions in the aging process and to promote their general well-being. The Company also distributes and sells biomedical drugs, medical
instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Currently,
the Company's products are sold in 30 provinces of China. For more information, visit the company's website at http://www.universe-pharmacy.com/.
Forward-Looking Statements
All statements other than statements of historical
fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties
and are based on current expectations and projections about future events and financial trends that the Company believes may affect its
financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements
by words or phrases such as "may," "will," "expect," "anticipate," "aim,"
"estimate," "intend," "plan," "believe," "potential," "continue,"
"is/are likely to" or other similar expressions. The Company undertakes no obligation to update forward-looking statements
to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the
Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations
will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results
and encourages investors to review other factors that may affect its future results in the Company's registration statement and
in its other filings with the U.S. Securities and Exchange Commission.
Chief Financial Officer of Universe Pharmaceuticals INC

Frequently Asked Questions

What notice did Universe Pharmaceuticals INC receive from Nasdaq?

Universe Pharmaceuticals INC received a staff determination notice for not filing its Form 20-F.

Why is Universe Pharmaceuticals facing potential delisting from Nasdaq?

The company is at risk of delisting due to its delinquency in filing the annual report.

What is the deadline for Universe Pharmaceuticals to request a stay?

The company must request a stay of suspension by February 26, 2025.

What products does Universe Pharmaceuticals INC specialize in?

The company specializes in traditional Chinese medicine derivatives and biomedical products.

Where is Universe Pharmaceuticals INC headquartered?

The company is headquartered in Ji'an, Jiangxi, China.

Last updated: Feb 25, 2025